Marie Thibault
Stock Analyst at BTIG
(3.45)
# 940
Out of 5,149 analysts
115
Total ratings
47.75%
Success rate
5.15%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $23 → $19 | $8.60 | +120.93% | 5 | Feb 26, 2026 | |
| DXCM DexCom | Reiterates: Buy | $85 | $73.08 | +16.31% | 10 | Feb 25, 2026 | |
| PODD Insulet | Reiterates: Buy | $380 | $241.84 | +57.13% | 7 | Feb 18, 2026 | |
| MASI Masimo | Downgrades: Neutral | n/a | $175.36 | - | 8 | Feb 18, 2026 | |
| ATRC AtriCure | Reiterates: Buy | $54 | $31.46 | +71.65% | 8 | Feb 18, 2026 | |
| OM Outset Medical | Maintains: Buy | $17 → $15 | $3.48 | +331.03% | 3 | Feb 12, 2026 | |
| EW Edwards Lifesciences | Reiterates: Buy | $103 | $85.28 | +20.78% | 3 | Feb 11, 2026 | |
| BSX Boston Scientific | Reiterates: Buy | $110 | $73.85 | +48.95% | 16 | Feb 9, 2026 | |
| EMBC Embecta | Reiterates: Buy | $25 | $9.71 | +157.47% | 4 | Feb 6, 2026 | |
| HAE Haemonetics | Reiterates: Buy | $88 | $65.63 | +34.09% | 5 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $2 | $0.53 | +280.01% | 3 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $17.54 | +71.04% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $140 | $113.61 | +23.23% | 15 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $23.04 | +38.89% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $215 | $125.85 | +70.84% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.36 | - | 2 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 → $65 | $71.11 | -8.59% | 8 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.85 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.27 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.83 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $406.41 | -98.52% | 1 | Apr 9, 2020 |
Delcath Systems
Feb 26, 2026
Maintains: Buy
Price Target: $23 → $19
Current: $8.60
Upside: +120.93%
DexCom
Feb 25, 2026
Reiterates: Buy
Price Target: $85
Current: $73.08
Upside: +16.31%
Insulet
Feb 18, 2026
Reiterates: Buy
Price Target: $380
Current: $241.84
Upside: +57.13%
Masimo
Feb 18, 2026
Downgrades: Neutral
Price Target: n/a
Current: $175.36
Upside: -
AtriCure
Feb 18, 2026
Reiterates: Buy
Price Target: $54
Current: $31.46
Upside: +71.65%
Outset Medical
Feb 12, 2026
Maintains: Buy
Price Target: $17 → $15
Current: $3.48
Upside: +331.03%
Edwards Lifesciences
Feb 11, 2026
Reiterates: Buy
Price Target: $103
Current: $85.28
Upside: +20.78%
Boston Scientific
Feb 9, 2026
Reiterates: Buy
Price Target: $110
Current: $73.85
Upside: +48.95%
Embecta
Feb 6, 2026
Reiterates: Buy
Price Target: $25
Current: $9.71
Upside: +157.47%
Haemonetics
Feb 6, 2026
Reiterates: Buy
Price Target: $88
Current: $65.63
Upside: +34.09%
Feb 5, 2026
Maintains: Buy
Price Target: $4 → $2
Current: $0.53
Upside: +280.01%
Jan 28, 2026
Reiterates: Buy
Price Target: $30
Current: $17.54
Upside: +71.04%
Jan 23, 2026
Maintains: Buy
Price Target: $145 → $140
Current: $113.61
Upside: +23.23%
Nov 18, 2025
Initiates: Buy
Price Target: $32
Current: $23.04
Upside: +38.89%
Oct 31, 2025
Maintains: Buy
Price Target: $195 → $215
Current: $125.85
Upside: +70.84%
Aug 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.36
Upside: -
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $71.11
Upside: -8.59%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.85
Upside: -
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.27
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $6.83
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $406.41
Upside: -98.52%